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Abstract
Introduction: Sepsis and its sequelae are the leading causes of morbidity and mortality in critically ill patients. The burden to healthcare
economies is also considerable. As the pathophysiology of sepsis is better defined, interventions aiming to treat sepsis are emerging.
Eritoran (E5564), a toll-like receptor 4 (TLR4)-directed endotoxin antagonist, is one such emerging therapeutic option for treatment
of sepsis.
Aims: This review assesses evidence for the potential therapeutic value of eritoran in the management of sepsis.
Evidence review: Evidence from a single phase II trial of eritoran usage in sepsis suggests that it is a safe and effective therapeutic
option for patients with sepsis, and is especially beneficial for patients at high risk of mortality. However, the cost effectiveness of eritoran
and its place in therapy compared with other available treatment options and those currently in development remains to be determined.
Clinical potential: Eritoran is a potential therapeutic option for management of sepsis and other TLR4- and lipopolysaccharide-
mediated disorders with a reasonable safety and tolerability profile that must be validated by several rigorous, blinded, placebo-
controlled, adequately powered, multicenter, randomized clinical trials.
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Core evidence proof of concept summary for eritoran in sepsis
Outcome measure Emerging evidence
Efficacy Potential to use as monotherapy in patients with newly diagnosed sepsis and endotoxemia; effective dose is 105 mg per 6 days
Response rates Some evidence that mortality is reduced by 13.0–17.6% in septic patients at highest risk of mortality
Marker of efficacy Most clinical studies do not report any constant marker of efficacy, although reduction in 28-day all-cause mortality appears to be
a reliable objective marker
Tolerability Good tolerability with daily dosing alone as well as with 72-hour continuous infusion
No consensus on maximum tolerated dose or dosage regimen
Safety Dose-dependent phlebitis most commonly experienced side effectScope, aims, and objectives
Sepsis is a generalized activation of the immune system in the
presence of clinically suspected or culture-proven infection.
Severe sepsis is sepsis with organ system dysfunction. Sepsis and
its sequelae are the leading causes of death in critically ill patients.
Advances in our understanding of the sepsis syndrome have
enabled researchers to identify new therapeutic targets and design
therapies for existing mediators of sepsis; one such therapeutic
target is toll-like receptor 4 (TLR4), which is involved in the
pathogenesis of sepsis and septic shock. Eritoran (E5564) is a
TLR4-directed endotoxin antagonist currently being investigated
for the treatment of severe sepsis, septic shock, and other
endotoxin-mediated indications. The objective of this article is to
present an overview of sepsis and current options in its treatment,
and to review the current evidence for the therapeutic potential of
eritoran in the management of sepsis and septic shock.
Methods
A literature search was conducted on July 6, 2007 in the following
databases using the search terms “Eritoran OR E5564.” The cut-
off date was from the beginning of the database to the date of
search unless otherwise stated:
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi, 1966 to
date. Search strategy “Eritoran OR E5564” limited to English
language results only
• EMBASE, http://www.datastarweb.com, 1974 to date. Search
strategy: “Eritoran OR E5564” limited to English language results
only
• Database of Abstracts of Reviews of Effects (DARE), National
Health Service (NHS) Economic Evaluation Database (NHSEED),
Health Technology Assessment (HTA),
http://www.york.ac.uk/inst/crd/darehp/htm. All three databases
searched together. All fields searched
• National Guideline Clearinghouse, http://www.guideline.gov
• National Institute for Health and Clinical Excellence (NICE),
http://www.nice.org.uk
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org/index.htm
• Eisai Inc.,
http://www.eisai.com/view_press_release.asp?ID=210&press
=124
After removal of duplicates, a total of 32 records were retrieved
from PubMed. Records were manually reviewed and any animal
studies, in-vitro studies, general narrative reviews, and articles
which mentioned eritoran but did not discuss trial data were
excluded. The remaining six records were included. In addition, a
further phase II trial conducted by Eisai Inc. was included
(Anon. 2005).
The identified studies were then classified into five classes of
evidence based on the design of the study, with level 1 evidence
presenting the strongest evidence and level 5 representing the
weakest evidence, as indicated in Table 1. No systematic reviews
or meta analyses were identified. Two phase II trials providing
level 2 evidence were retrieved, one a full manuscript and another
an abstract. Publications relating to pharmacoeconomic evidence
with eritoran were not identified.
Disease overview
Incidence of sepsis
Sepsis remains a critical problem with significant morbidity and
mortality even in the modern era of critical care management.
Multiple derangements exist in sepsis involving several different
organs and systems, although controversies exist over their
individual contribution to the disease process (Remick 2007). The
reported rates of severe sepsis average around 10 cases per
100 intensive care unit (ICU) admissions (Linde-Zwirble & Angus
2004). Epidemiologic studies of the incidence of sepsis indicate
that between 11% and 27% of ICU admissions have severe
sepsis (Kleinpell et al. 2006). Estimates of the incidence of sepsis
in adult patients vary from 51 per 100 000 in England and Wales
(Padkin et al. 2003) to 77 per 100 000 in Australia and New
Zealand (Finfer et al. 2004) and 240 per 100 000 in the USA
(Martin et al. 2003). Mortality remains high (20–50%) and sepsis is
consistently reported as a leading cause of death in noncardiac
ICUs (Angus et al. 2001; Dremsizov et al. 2004). Severe sepsis has
a significant impact on quality of life, with survivors of severe
sepsis having substantial impairment (Heyland et al. 2000;
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Category Number of records
Full papers Abstracts
Initial search 32 0
records excluded 26 0
records included 6 0
Additional studies identifieda 1 0
records excluded 0 0
records included 0 1
Level 1 clinical evidence
(systematic review, meta analysis)
0 0
Level 2 clinical evidence (RCT) 1 1
Level ≥3 clinical evidence 6 0
trials other than RCT 3 0
case reports 0 0
pharmacokinetic studies 2 0
pharmacodynamic studies 1 0
Economic evidence 0 0
For definition of levels of evidence, see Editorial Information on inside back cover or on
Core Evidence website (http://www.coremedicalpublishing.com).
aAny relevant study that was identified from a source other than the main searches,
e.g. a reference list.
RCT, randomized controlled trial.
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Korosec Jagodec et al. 2006). Care of septic patients in the ICU
also imposes considerable burden on healthcare economies. It
has been estimated that in the USA the average expenditure per
patient is around $US22 000, with a total annual cost approaching
$US17 billion (Angus & Wax 2001). The median daily costs of care
for septic patients at the time of admission to the ICU are
$US930.74 (interquartile range, $US851.59 to $US1263.96) in the
UK (Edbrooke et al. 1999).
Pathophysiology of sepsis
Emerging evidence regarding the pathophysiology of sepsis, or
systemic inflammatory response syndrome (SIRS) caused by
infection, suggests that all pathogenic organisms have pathogen-
or microorganism-associated molecular patterns (PAMPs) that
can initiate a septic response (Cohen 2002). PAMPs bind to
pattern recognition receptors, of which three families are central
to the pathogenesis of septic response, namely TLRs, nucleotide-
oligomerization domain (NOD) leucine-rich repeat proteins, and
retinoic-acid-inducible gene 1-like (RIG-1) helicases (Uematsu &
Akira 2006). TLRs are predominantly present on the surface of
immune cells and play a major role in human innate immunity
(Verstak et al. 2007).
Binding of TLRs activates intracellular signal-transduction
pathways that lead to the activation of cytosolic nuclear factor-
ʺB. Activated nuclear factor-ʺB moves from the cytoplasm to the
nucleus, binds to transcription sites, and induces activation of a
set of genes, as well as enzymatic activation of a cellular
protease. TLRs induce pro-interleukin-1-beta (IL-1-beta)
production and prime NOD-like receptor-containing multiprotein
complexes, termed “inflammasomes,” to respond to bacterial
products and products of damaged cells. This results in
caspase-1 activation and the subsequent processing of
pro-interleukin-1-beta to its active form (Trinchieri & Sher 2007).
Thus, TLR-mediated dysregulation of the immune response to
pathogens results in organ dysfunctions in severe sepsis.
Concomitant phenotypic modification of the endothelium
including changes in procoagulant and proadhesive properties,
increased endothelial permeability, endothelial cell apoptosis, and
changes in vasomotor properties leading to vasoplegia, further
contribute to the morbidity and mortality associated with septic
shock (Aird 2007).
During sepsis, in addition to extensive stimulation of the innate
immune system and phenotypic modification of the endothelium,
white blood cell activation and complement system activation
leads to the release of a number of mediators or cytokines (Jean-
Baptiste 2007). These include the release of IL-1, IL-2, IL-4, IL-6,
IL-8, IL-10, tumor necrosis factor-alfa (TNF-alfa), platelet-
activating factor, endorphins, nitric oxide, reactive oxygen
species, tissue factor, macrophage migration inhibitory factor, and
chemokines, which lead to a variety of immune system responses
including vasodilatation, enhanced expression of adhesion
molecules, increased capillary permeability, increased clot
formation, and decreased fibrinolysis. Free radicals are generated
by leucocytes, including neutrophils and monocytes, during
inflammation and lead to proinflammatory and ischemia-induced
injury (Kleinpell et al. 2006; Jean-Baptiste 2007).
Side by side with the proinflammatory response, activation of
counterinflammatory mechanisms and the release of
antiinflammatory cytokines also takes place. Antagonists, such as
soluble TNF receptors, IL-1 receptor type II, complement
inactivators, and antiinflammatory cytokines such as IL-10 and
IL-4, are released. Furthermore, extensive lymphocyte-
programmed cell death (apoptosis), conversion of
proinflammatory cytokine-producing type 1 helper T cells to
antiinflammatory cytokine-producing type 2 helper T cells, and
permanent T cell unresponsiveness also occurs (Kleinpell et al.
2006). It is theorized that this antiinflammatory response aimed
primarily at counteracting overamplified proinflammatory
response of sepsis in reality hampers the ability of the body to
combat the triggering infectious event when overamplified itself
(Cavaillon & Annane 2006).
A large number of coagulation, cardiovascular, metabolic, and
endocrine abnormalities further contribute to multiple organ
dysfunction syndrome, the eventual cause of death in sepsis.
These include a procoagulant state with formation of
microthrombi, disseminated intravascular coagulation, impaired
cardiac contractility, adrenal insufficiency, vasopressin deficiency
leading to vasoplegia, and—last but not least—insulin deficiency
and its sequelae such as impaired wound healing, reduced
granulocyte function, and increased risk of infections (Tsiotou et
al. 2005).
Current therapy options
Surviving Sepsis Campaign guidelines
The treatment of severe sepsis includes three essential principles:
eradication of the inciting infection using source control measures
and empiric antibiotics, hemodynamic resuscitation of
hypoperfusion to avoid acute life-threatening organ dysfunction,
and sustained support of organ system dysfunction using
interventions that minimize organ injury (Cinel & Dellinger 2006).
Therapy can be divided into immediate steps taken to stabilize
the patient, followed by more definitive therapeutic intervention.
The evidence for best clinical practice for resuscitation,
management of infection, and ICU supportive care has recently
been synthesized by the Surviving Sepsis Campaign and
published as evidence-based guidelines for management of
severe sepsis and septic shock (Cinel & Dellinger 2006).
The Surviving Sepsis Campaign was launched in 2002 by the
Society of Critical Medicine, the European Intensive Care Society,
and the International Sepsis Forum. The aim of this collaboration
was to improve the standard of care offered to patients with
sepsis, with the hope of reducing mortality due to sepsis by 25%
by the year 2007 (Poulton 2006). Under the auspices of the
campaign, international experts reviewed the relevant literature
available, with the goal of producing guidelines that would be of
practical use in the management of the septic patient. These
guidelines covering more than 50 areas of sepsis management
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critical care, and nursing organizations suggest a “resuscitation
bundle” and a “management bundle” aimed at achieving the goal
of a 25% reduction in mortality from severe sepsis (Dellinger et
al. 2004).
The Severe Sepsis Resuscitation Bundle describes seven tasks
(Table 2) that should begin immediately, but must be
accomplished within the first 6 hours of presentation for patients
with severe sepsis or septic shock. Some items may not be
completed if the clinical conditions described in the bundle do not
prevail in a particular case, but clinicians must assess for them.
The goal is to perform all indicated tasks 100% of the time within
the first 6 hours of identification of severe sepsis (IHI 2007).
The Sepsis Management Bundle lists four management tasks
(Table 3). Efforts to accomplish these tasks should also begin
immediately, but these items may be completed within 24 hours
of presentation for patients with severe sepsis or septic shock
(IHI 2007).
Therapeutic options with strong evidence base (evidence
level 2)
Early goal-directed therapy
Early goal-directed therapy is an algorithmic approach to
restoration of systemic oxygen delivery through a manipulation of
preload (volume), afterload (blood pressure), and contractility
(stroke volume) guided by central venous pressure, mean arterial
pressure, and central venous oxygen saturation monitoring to
preserve effective tissue perfusion within the first 6 hours of
disease presentation (Nguyen & Smith 2007).
Early timing of hemodynamic intervention is critical, and it is
extremely important that only normal, rather than supranormal,
goals should be sought (Rivers et al. 2001). This concept has
been validated by two large, randomized controlled trials which
showed that supranormal hemodynamic goals, started at various
points in the course of the sepsis process, had no impact on survival
(Hayes et al. 1994; Gattinoni et al. 1995). The efficacy of early goal-
directed therapy or early hemodynamic optimization was proven in
a randomized controlled trial involving 263 patients with infection
associated with hypotension after a fluid bolus and/or serum lactate
≥4 mmol/L who were randomly assigned to receive standard
resuscitation or early goal-directed therapy in the emergency
department before ICU transfer. During the first 6 hours in the
emergency department, the early goal-directed therapy group had
significantly greater amount of fluid therapy than the control group
(5.0 vs 3.5 L, respectively), red blood cell transfusion (64.1% vs
18.5%, respectively), and inotrope (dobutamine) administration
(13.7% vs 0.8%, respectively). The primary outcome variable,
in-hospital mortality, was 46.5% in the control group versus 30.5%
in the early goal-directed therapy group (P=0.009). Of the patients
who survived to hospital discharge, early goal-directed therapy
resulted in a significant 3.8-day shorter length of hospital stay
(P=0.04). The early goal-directed therapy was associated with a
significant two-fold decrease in the incidence of sudden
cardiopulmonary complications, such as cardiac arrest,
hypotension, or acute respiratory failure (P=0.02) (Rivers et al. 2001).
Activated drotrecogin alfa rhAPC (recombinant human activated
protein C)
Activated protein C (APC) has antiinflammatory, antithrombotic, and
fibrinolytic actions (Esmon 2001). Production of endogenous APC is
reduced in patients with sepsis due to downregulation of
thrombomodulin (Nguyen & Smith 2007) and there is an inverse
relationship between the level of protein C and the risk of mortality
in these patients (Fourrier et al. 1992). This fact was verified by the
investigators of the PROWESS study (Bernard et al. 2001).
The PROWESS study, a randomized, double-blind, placebo-
controlled trial, was conducted at 164 centers in 11 countries.
Patients with three SIRS criteria and at least one organ failure of less
than 24 hours’ duration were eligible for the trial. A total of
1690 patients were randomized to receive activated drotrecogin alfa
(24 mcg/kg per hour) or placebo for 96 hours. The primary endpoint
for the trial was mortality at 28 days. The trial was terminated at
second interim analysis because of the survival advantage found for
activated drotrecogin alfa. The 28-day mortality was 30.8% in the
placebo group and 24.7% in the drotrecogin alfa group, indicating a
relative risk reduction of 19.4% [95% confidence interval (CI) 6.6%,
30.5%]. The absolute risk reduction was greater (12.8%) in those
patients at greatest risk [Acute Physiology and Chronic Health
Evaluation (APACHE) II scores >25]. Reductions in the relative risk of
death were seen regardless of the baseline level of APC (Bernard et
al. 2001).
As expected from the antithrombotic activity of activated
drotrecogin alfa, bleeding was the most common adverse incident
associated with the drug. The authors estimated that one additional
serious bleeding event would occur for every 66 patients treated.
Patients with a predisposing history were most at risk (Bernard et
al. 2001).
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1. Serum lactate measured
2. Blood cultures obtained prior to antibiotic administration
3. Improve time to antibiotic administration
4. Treat hypotension and/or elevated lactate with fluids
5. Administer vasopressors for ongoing hypotension
6. Maintain adequate central venous pressure
7. Maintain adequate central venous oxygen saturation
Table 2 | The tasks of the Severe Sepsis Resuscitation
Bundle (IHI 2007)
1. Administer low-dose steroids by a standard policy
2. Administer activated protein C (drotrecogin alfa) by a standard policy
3. Maintain adequate glycemic control
4. Prevent excessive inspiratory plateau pressures
Table 3 | The tasks of the Sepsis Management Bundle
(IHI 2007)203
Activated drotrecogin alfa has Food and Drug Administration
approval and is currently recommended in patients at high risk of
death [APACHE II scores ≥25, sepsis-induced multiple organ
failure, septic shock, or sepsis-induced acute respiratory distress
syndrome (ARDS)] and with no absolute contraindication related
to bleeding risk or relative contraindication that outweighs the
potential benefit.
Protective ventilation of patients with sepsis-induced acute lung
injury/ARDS
The traditional approach to ventilation in patients with acute lung
injury (ALI)/ARDS has been to aim for a normal partial pressure of
CO2 (PaCO2) and pH. However, because there are fewer
functioning alveoli, there is much greater stretching than usual in
these functional alveoli if normal tidal volumes are maintained. It
has been demonstrated that volutrauma to alveoli induces release
of proinflammatory cytokines, which in turn leads to a
perpetuation of the process (Poulton 2006). The Surviving Sepsis
Campaign guidelines recommend that high tidal volumes that are
coupled with high plateau pressures should be avoided in
ALI/ARDS. Clinicians should use as a starting point a reduction in
tidal volumes over 1–2 hours to a low tidal volume (6 mL/kg
predicted body weight) as a goal, in conjunction with the goal of
maintaining end-inspiratory pressures <30 cm H2O.
A small randomized controlled trial conducted in Brazil, recruiting
53 patients with early ARDS, was the first to suggest a dramatic
improvement in mortality when lower tidal volumes were used at
the expense of a higher PaCO2 (Amato et al. 1998). The patients,
all of whom were receiving identical hemodynamic and general
support, were subjected to conventional or protective mechanical
ventilation. Conventional ventilation was based on the strategy of
maintaining the lowest positive end-expiratory pressure (PEEP)
for acceptable oxygenation, with a tidal volume of 12 mL/kg of
bodyweight and normal arterial carbon dioxide levels (35 to
38 mmHg). Protective ventilation involved end-expiratory
pressures above the lower inflection point on the static
pressure–volume curve, a tidal volume of less than 6 mL/kg,
driving pressures of less than 20 cm of water above the PEEP
value, permissive hypercapnia, and preferential use of pressure-
limited ventilatory modes. After 28 days, 11 of 29 patients (38%)
in the protective-ventilation group had died, compared with 17 of
24 (71%) in the conventional-ventilation group (P<0.001). The
rates of weaning from mechanical ventilation were 66% in the
protective-ventilation group and 29% in the conventional-
ventilation group (P=0.005); the rates of clinical barotrauma were
7% and 42%, respectively (P=0.02), despite the use of higher
PEEP and mean airway pressures in the protective-ventilation
group. The difference in survival to hospital discharge was not
significant; 13 of 29 patients in the protective-ventilation group
died in the hospital, compared with 17 of 24 in the conventional-
ventilation group (45% vs 71%, P=0.37).
The results of the Brazilian trial prompted the US ARDS Network
to evaluate the strategy in a large, multicenter, randomized
controlled trial in which patients with ALI or ARDS were
randomized to receive ventilation with tidal volumes of 12 mL/kg
(control) or 6 mL/kg (treatment). The primary endpoint for the trial
was death before discharge home. The trial was stopped early
after enrollment of 861 patients. The low tidal volume group had a
mortality of 31% compared with 39.8% in the control group
(P=0.007). Those patients with low tidal volumes also spent fewer
days on ventilatory support and had lower levels of circulating
IL-6 (Anon. 2000).
Low-dose steroids
The role of systemic administration of corticosteroids in modifying
the course and outcome of septic shock has been the subject of
considerable debate since the 1950s (Sessler 2003). Despite the
many proven antiinflammatory properties of corticosteroids, the
wealth of favorable studies utilizing various animal models of
septic shock, and many anecdotal positive reports in clinical
sepsis, until recently multicenter clinical trials had generally failed
to support this form of treatment (Anon. 1987; Bone et al. 1987). In
fact, there is now widespread agreement that high-dose, short-
course therapy with methylprednisolone or dexamethasone in
septic shock is ineffective. In contrast, the new paradigm of
prolonged treatment with low- to modest-dose hydrocortisone for
relative adrenal insufficiency in septic shock is attracting attention.
Support for this new paradigm is provided by three randomized
controlled trials (Bollaert et al. 1998; Briegel et al. 1999; Annane
et al. 2002). The largest of these trials was conducted in France
involving 19 ICUs (Annane et al. 2002). In this study
300 patients with septic shock were randomized to receive either
placebo or hydrocortisone 50 mg four times a day and
fludrocortisone 50 mcg once a day. Treatment was continued for
7 days if survival time was sufficient. A short synacthen test was
performed on all patients at randomization. The primary outcome
measure was 28-day mortality.
A total of 229 patients had an inadequate response to synacthen.
In these nonresponders, 28-day mortality was significantly lower in
those patients treated with steroids (53%) compared with those
assigned to placebo (63%) (hazard ratio 0.67; 95% CI 0.47, 0.95;
P=0.02). Patients assigned to receive steroids were also weaned
from inotropic support more rapidly and received lower doses of
inotropes. There was no apparent survival advantage for steroid
treatment in those patients who had demonstrated an adequate
response to synacthen.
Based on the findings of this trial the Surviving Sepsis Campaign
guidelines recommend that intravenous corticosteroids
(hydrocortisone 200–300 mg/day for 7 days in three or four divided
doses or by continuous infusion) are administered to patients with
septic shock who, despite adequate fluid replacement, require
vasopressor therapy to maintain adequate blood pressure.
Intensive insulin therapy
The Surviving Sepsis Campaign guidelines recommend that
following initial stabilization of patients with severe sepsis, blood
glucose is maintained at <8.3 mmol/L. Critically ill patients have
hyperglycemia and raised levels of insulin-like growth factor
Eritoran | proof of concept review
Core Evidence 2007;2(3)binding protein-1. The latter reflects an impaired hepatic response
to insulin and has an inverse relationship with the likelihood of
survival (Poulton 2006), hence intensive insulin therapy appears
an attractive therapeutic option in septic patients.
The randomized controlled trial that forms the basis of the
Surviving Sepsis Campaign recommendation regarding tight
glycemic control was conducted in Belgium and randomized
1548 surgical intensive care patients to receive tight blood
glucose control (4.4–6.1 mmol/L) or a more traditional target
(10–11 mmol/L). Almost all patients (98.7%) allocated to tight
control needed insulin, whereas only 39% of the control group
did (van den Berghe et al. 2001).
There was a statistically significant difference in intensive care
mortality, and this was principally attributable to long-stay
patients. In long-stay patients with tight control, there was a
four-fold reduction in deaths due to sepsis-induced multiple
organ failure, whereas other causes of death were similar
between the two groups. Intensive insulin therapy also
appeared to reduce overall in-hospital mortality by 34%. Other
advantages to tight blood glucose control included shorter
intensive care times, a reduced risk of renal failure and, most
significantly, a much lower incidence of critical illness
polyneuropathy.
Therapeutic options with proven clinical benefit but weak
evidence base (evidence level 4/5)
Antimicrobial therapy
Delay in instituting antimicrobial therapy after the onset of
hypotension in patients with septic shock is associated with a
significant increase in mortality (Nguyen & Smith 2007). This fact
has been highlighted by a large retrospective cohort study of
2154 septic shock patients in 14 ICUs in Canada and the United
States (Kumar et al. 2006). The study showed that each hour of
delay in antibiotic administration during the first 6 hours of
persistent hypotension was associated with a 7.6% increase in
mortality (range, 3.6–9.9%). The odds ratio for mortality was
1.67 (95% CI 1.12, 2.48) if the delay was 1 hour and continued to
increase with progressive delays to a maximum value of
92.54 (95% CI 44.92, 190.53) for delays more than 36 hours after
the onset of hypotension.
Interestingly, the guidelines pertaining to antimicrobial therapy are
not supported by a strong evidence base, yet they are not
controversial and are certainly in line with current mainstream
practice. These guidelines are summarized in Table 4.
Unmet needs
Therapy for sepsis remains unsatisfactory despite a concerted
effort to develop new treatments for this common, life-
threatening syndrome. Current research continues on several
fronts to improve the treatment options available to clinicians in
the management of these critically ill patients. Recently, a
greater understanding of the complex molecular basis of
endotoxin-mediated pathophysiologic effects in humans has
generated a number of novel therapeutic agents for sepsis.
Several of these treatment strategies have already entered clinical
trials and it is hoped that some of these therapies will become
widely available in the near future.
Outcomes achieved with eritoran in clinical
development
Eritoran is a second-generation TLR4-directed lipopolysaccharide
(LPS) antagonist derived from the structure of Rhodobacter
sphaeroides (Mullarkey et al. 2003). Clinically, eritoran is being
investigated for the treatment of severe sepsis, septic shock, and
other endotoxin-mediated indications.
Efficacy
The therapeutic potential of eritoran as an effective treatment for
sepsis and endotoxemia in humans was first highlighted by a
randomized, double-blind, placebo-controlled study published in
2003 (Lynn et al. 2003). The study recruited 24 healthy male
volunteers, aged 18–45 years (mean 30.1 years) and weighing
55.5–104.5 kg (mean 76.7 kg). Subjects were randomly assigned to
receive eritoran or placebo (ratio of 6:2 per dose level). The first
cohort of eight subjects assigned to active drug received 250 mcg
as a single 30 min intravenous infusion. Subjects in the other two
groups assigned to active drug received 100 or 50 mcg. Subjects
assigned to the placebo group in each cohort received similar
intravenous infusions. All subjects received an intravenous dose of
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Guideline Evidence
level
1. Intravenous antibiotic therapy should be started within the
first hour of the recognition of severe sepsis, after
appropriate cultures have been obtained. It is also
recommended that premixed antibiotics should be available
to increase the likelihood of early administration
5
2. Choice of initial antibiotics should be empirical, but should
clearly be guided by the clinical picture and the sensitivity
patterns of local pathogens
4
3. Broad-spectrum antibiotics should be used until the
causative organism is identified. At 48–72 hours, antibiotic
treatment should be reviewed. At this point, the spectrum
should be narrowed if appropriate. The rationale for this
recommendation is that it will help to contain costs and
reduce the risk of emergence of resistant organisms. The
duration of treatment should typically be 7–10 days and
guided by clinical response
5
4. Some experts prefer combination therapy for patients with
Pseudomonas infections, regardless of sensitivities
5
5. Most experts would continue to use combination therapy for
neutropenic patients with severe sepsis or septic shock
5
6. If the presenting SIRS is determined to be due to a
noninfective cause, antibiotic therapy should be stopped
promptly to minimize the risk of development of
resistant pathogens
5
SIRS, systemic inflammatory response syndrome.
Table 4 | Guidelines pertaining to antimicrobial therapy
in sepsis205
LPS 4 ng/kg, 15 min after the start of the study drug infusion to
produce experimental endotoxemia.
The results of the study revealed that single eritoran doses of
50–250 mcg ameliorated or blocked all of the effects of LPS
in a dose-dependent manner. All eritoran dose groups had
statistically significant reductions in elevated temperature, heart
rate, C-reactive protein levels, white blood cell count, and
cytokine levels (TNF-alfa and IL-6), compared with placebo
(P<0.01). In doses of ≥100 mcg, eritoran acted as an LPS
antagonist and completely eliminated these signs. Eritoran also
blocked or ameliorated LPS-induced fever, chills, headache,
myalgia, and tachycardia (P<0.01).
To date, one large phase II trial has been conducted to assess the
efficacy of eritoran for the management of sepsis. The study,
conducted in North America, involved 293 patients randomized to
three groups: eritoran high dose (105 mg per 6 days), eritoran low
dose (45 mg per 6 days), and placebo (Anon. 2005). Eritoran was
administered twice daily by intravenous infusion. The goal of this
study, with 80% patient compliance, was to test whether eritoran
could reduce the 28-day all-cause mortality by at least 5%
compared with placebo. The study was not sized to detect a
statistically significant difference in mortality and P values were
only of exploratory nature. Patients who received high-dose, but
not low-dose, eritoran experienced a reduction in 28-day all-
cause mortality of 6.4%, compared with placebo recipients
(P=0.34). Moreover, patients who were considered to have the
highest risk of death experienced reductions in mortality of 13%
(P=0.17) and 17.6% (P=0.07) after treatment with low- and high-
dose eritoran, respectively, compared with placebo recipients.
A recently published ex-vivo laboratory study has also shown that
eritoran in doses of 0.03 ng/mL up to 10 ng/mL causes a dose-
dependent inhibitory effect on IL-6 and TNF-alfa production in
LPS-stimulated human monocytes (Czeslick et al. 2006).
Safety and tolerability
Safe treatment with eritoran requires that it generates no LPS-like
response on its own.
In the North American phase II trial the drug appeared to be well
tolerated. Phlebitis, or inflammation of the vein, was observed in
6.7% of patients receiving eritoran through a peripheral vein, and
showed a tendency to recover with time (Eisai Inc. 2005).
An earlier study to determine safety, pharmacokinetics,
pharmacodynamics, and plasma lipoprotein distribution of
eritoran during continuous intravenous infusion in healthy
volunteers also demonstrated that the drug was safe and well
tolerated (Rossignol et al. 2004). This study was a single-center,
randomized, double-blind, placebo-controlled, 72-hour infusion,
sequential-group study of eritoran in healthy male volunteers (five
eritoran-treated and two placebo-treated subjects per dose
group). Three doses of eritoran (500, 2000, and 3500 mcg/hour)
were studied. Eritoran or matching placebo was administered as
a 72-hour intravenous infusion.
Subjects were observed during the 72-hour infusion and for up to
144 hours following infusion. The only adverse events that
occurred more than once in these subjects were: headache in
three eritoran-treated subjects (19%) versus four subjects (19%)
in the placebo group; rhinitis in two subjects (13%) in the eritoran-
treated group; and a self-limiting phlebitis in 57% of the subjects
in the placebo group versus 83% of the subjects in the eritoran
500 mcg/hour group and all subjects in the 2000 and
3500 mcg/hour groups. Differences in occurrence of phlebitis
between subject groups were not statistically significant, and
although there was a trend of worsening severity of phlebitis in the
higher dose groups, differences again did not reach statistical
significance. This was perhaps due to the fact that the study was
not powered to draw such a conclusion.
Furthermore, no dose adjustment is needed in patients with
hepatic impairment. In a study to assess the pharmacokinetics of
eritoran in patients with impaired hepatic function, the drug was
administered via intermittent intravenous infusion every 12 hours
for six times, to 24 hepatic-impaired patients (12 each to Child-
Pugh Classifications A and B) and 24 matching healthy
volunteers. The results of the study showed that none of the
pharmacokinetic parameters exhibited any difference between
these two groups (Liang et al. 2003).
Patient group/population
Available evidence from the North American phase II trial
suggests that the greatest benefit of eritoran therapy is likely to be
seen in the population at the highest risk of mortality due to
sepsis. In patients who were considered at higher risk of death in
this trial, mortality was 50.9% among placebo recipients, 37.9%
in low-dose patients, and 33.3% in high-dose patients. The
reduction of mortality in low- and high-dose patients compared
with placebo was 13.0% (P=0.17) and 17.6% (P=0.07),
respectively, confirming the survival benefit of eritoran. However,
it is important to note that in this study P values were only of
exploratory nature.
Eritoran may also be useful in other LPS-related diseases. One
such patient group which may benefit from eritoran therapy is the
population undergoing cardiac surgery. LPS enters the systemic
circulation by leakage from the intestinal lumen during surgery,
most likely as a result of mesenteric hypoperfusion (Nilsson et al.
1990). Endotoxin levels are in the range of several 100 pg/mL
during cardiopulmonary bypass (Rocke et al. 1987). Further
evidence implicates endotoxin as one factor that may contribute
to poor surgical outcome after cardiac surgery (Bennett-Guerrero
et al. 2007).
A double-blind, randomized, ascending-dose, placebo-
controlled study was recently conducted at nine hospitals in
North America to evaluate safety of eritoran administration in
patients undergoing cardiac surgery and obtained preliminary
efficacy data for the prophylaxis of endotoxin-mediated surgical
complications (Bennett-Guerrero et al. 2007). Patients
undergoing coronary artery bypass graft and/or cardiac valvular
surgery with cardiopulmonary bypass were enrolled. Patients
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12 mg (n=26), or 28 mg (n=24) of eritoran initiated approximately
1 hour before cardiopulmonary bypass. No significant safety
concerns were identified with continuous safety monitoring, and
enrollment continued to the highest prespecified dose (28 mg).
No statistically significant differences were observed in most
variables related to systemic inflammation or organ
dysfunction/injury.
The fact that the drug may not have been administered long
enough or the total dose may have been insufficient, the
possibility that endotoxin may be a cause of systemic
inflammation but not the primary cause in cardiac surgery
patients, and that the trial was not sufficiently powered to
determine differences in clinical outcomes, may be some of the
reasons that explain the lack of a demonstrable effect of eritoran
on variables related to systemic inflammation in cardiac
surgical patients.
Clinical potential
Current best available evidence from a single phase II trial of
eritoran usage in sepsis suggests that it is a safe and effective
therapeutic option for patients with sepsis and is especially
beneficial for patients at high risk of mortality. However, it is
extremely important to realize that presently there are few data
on effects of long-term eritoran therapy for sepsis and other
potential indications. The available evidence contributes to a
building sense of excitement that eritoran may be an effective
treatment in sepsis and other LPS-related disorders, especially
as eritoran targets TLRs such as TLR4 and has the ability to
block the proinflammatory response to LPS or heat shock
proteins. However, the duration of therapy and dosage of
eritoran for these conditions has still not been established.
Moreover, eritoran therapy in most of the novel LPS-related
indications as well as sepsis will require continuous exposure
to possibly larger doses, suggesting that adverse effects may
be more widespread, contrary to what has been suggested so
far by the solitary phase II trial and small single-dose studies.
Finally, important data on the economic impact of eritoran
therapy and its comparative efficacy with other therapeutic
options for management of sepsis as well as its use in the
pediatric population are currently missing.
Because so many novel therapies in the past have not lived up
to their initial promise, we should protect our patients (and
ourselves) and refrain from empirically administering eritoran
for treatment of sepsis and other emerging indications at
present. Several rigorous, blinded, placebo-controlled,
adequately powered multicenter, randomized clinical trials
evaluating the impact of eritoran therapy on resource utilization
as well as long-term safety and efficacy are required to validate
the routine use of this novel TLR4-directed endotoxin
antagonist in sepsis.
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